Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05963282
Status:
COMPLETED
Last Update Posted:
2023-07-27
First Post:
2023-07-19
Brief Title:
Comparative Effectiveness of Entresto SacubitrilValsartan Versus ACEiARB in de Novo Heart Failure Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Comparative Effectiveness of Entresto SacubitrilValsartan Versus ACEiARB in de Novo Heart Failure Patients
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a non-interventional retrospective cohort study of de novo heart failure with reduced ejection fraction HFrEF patients aged 18 years commencing first-line treatment on either sacubitrilvalsartan or commencing or continuing angiotensin-converting enzyme inhibitors ACEiangiotensin receptor blocker ARB therapy for HF in the United States US using the secondary source of data Optum Electronic Health Records EHR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None